Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Streptozotocin (STZ) is currently the most used diabetogenic agent in testing insulin and new antidiabetic drugs in animals. Due to the toxic and disruptive nature of STZ on organs, apart from pancreas, involved in preserving the body's normal glucose homeostasis, this study aims to reassess the action of STZ in inducing different glucose response states in diabetic rats while testing insulin. Diabetic Sprague-Dawley rats induced with STZ were classified according to their initial blood glucose levels into stages. The effect of randomizing rats in such a manner was investigated for the severity of interrupting normal liver, pancreas, and kidney functions. Pharmacokinetic and pharmacodynamic actions of subcutaneously injected insulin in diabetic and nondiabetic rats were compared. Interruption of glucose homeostasis by STZ was challenged by single and repeated administrations of injected insulin and oral glucose to diabetic rats. In diabetic rats with high glucose (451-750 mg/dL), noticeable changes were seen in the liver and kidney functions compared to rats with lower basal glucose levels. Increased serum levels of recombinant human insulin were clearly indicated by a significant increase in the calculated maximum serum concentration and area under the concentration-time curve. Reversion of serum glucose levels to normal levels pre- and postinsulin and oral glucose administrations to STZ diabetic rats were found to be variable. In conclusion, diabetic animals were more responsive to insulin than nondiabetic animals. STZ was capable of inducing different levels of normal glucose homeostasis disruption in rats. Both pharmacokinetic and pharmacodynamic actions of insulin were altered when different initial blood glucose levels of STZ diabetic rats were selected for testing. Such findings emphasize the importance of selecting predefined and unified glucose levels when using STZ as a diabetogenic agent in experimental protocols evaluating new antidiabetic agents and insulin delivery systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas
Szkudelski, T. (2001) · Physiological Research · doi:10.33549/physiolres.930111 · Cited by 2,876 · cited 1×
“STZ can also liberate nitric oxide inside the cells that inhibits aconitase activity resulting in further DNA damage.(16) Indeed such toxic activity is more pronounced in β cells in pancreas leaving α and γ cells intact.”
BackgroundThe mechanisms of alloxan- and streptozotocin-induced diabetes
Lenzen, S. (2008) · Diabetologia · doi:10.1007/s00125-007-0886-7 · Cited by 2,290
The use of animal models in diabetes research
King, A. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01911.x · Cited by 1,303 · cited 2×
“Nevertheless, the most common method for inducing diabetes in animals is the use of diabetogenic drugs that include alloxan monohydrate,(2,3) streptozotocin (STZ) with or without nicotinamide,(4,5) ferric nitrilotriacetate,(6) dithizone,(7) and many other chemicals.(1,8) According to the literature, STZ is considered…”
BackgroundStudies on the diabetogenic action of streptozotocin (NSC-37917).
Rakieten, N., Rakieten, M. L., & Nadkarni, M. (1963) · PubMed · Cited by 967
Deeds, M. C., Anderson, J. M., Armstrong, A. S., Gastineau, D. A., Hiddinga, H. J., Jahangir, A., Eberhardt, N. L., & Kudva, Y. C. (2011) · Laboratory Animals · doi:10.1258/la.2010.010090 · Cited by 605
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540
Studies on the Diabetogenic Action of Streptozotocin (NSC37917)
Raikieten, N. (1963) · Medical Entomology and Zoology · Cited by 443
Streptozotocin–nicotinamide-induced diabetes in the rat. Characteristics of the experimental model
Szkudelski, T. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2012.011372 · Cited by 436
Responses of Neonatal Rat Islets to Streptozotocin: Limited B-Cell Regeneration and Hyperglycemia
Bonner-Weir, S., Trent, D. F., Honey, R. N., & Weir, G. C. (1981) · Diabetes · doi:10.2337/diab.30.1.64 · Cited by 324
Awai, M., Narasaki, M., Yamanoi, Y., & Seno, S. (1979) · PubMed Central · Cited by 272
Animals models for studying diabetes mellitus.
Etuk, E. U. (2010) · Agriculture and Biology Journal of North America · Cited by 255
Strain Differences in the Diabetogenic Activity of Streptozotocin in Mice
Hayashi, K., Kojima, R., & Ito, M. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1110 · Cited by 205 · cited 2×
“STZ is a pancreatic-selective β-cell toxin that induces random and rapid and irreversible necrosis of β cells.(4,10) Its β-cell specificity is mainly the result of selective cellular uptake and accumulation.”
BackgroundPrinciples of Diabetes Mellitus
(2010) · Springer eBooks · doi:10.1007/978-0-387-09841-8 · Cited by 183
Acute and chronic animal models for the evaluation of anti-diabetic agents
Kumar, S. G., Singh, R., Vasudeva, N., & Sharma, S. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-9 · Cited by 153 · cited 1×
“Nevertheless, the most common method for inducing diabetes in animals is the use of diabetogenic drugs that include alloxan monohydrate,(2,3) streptozotocin (STZ) with or without nicotinamide,(4,5) ferric nitrilotriacetate,(6) dithizone,(7) and many other chemicals.(1,8) According to the literature, STZ is considered…”
Antihyperglycaemic and protective effects of flavonoids on streptozotocin–induced diabetic rats
Rauter, A. P., Martins, A., Borges, C., Mota‐Filipe, H., Pinto, R., Sepodes, B., & Justino, J. (2010) · Phytotherapy Research · doi:10.1002/ptr.3017 · Cited by 138
Selective degradation of insulin within rat liver endosomes.
Doherty, J. J., Kay, D. G., Lai, W. H., Posner, B. I., & Bergeron, J. J. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.1.35 · Cited by 105 · cited 1×
“This strongly suggests that insulin clearance, due to liver degradation and kidney elimination, was reduced since it was reported that the liver and kidneys are the major organs for insulin turnover in blood.(18,21,22) Consequently, the effect of insulin in the STZ diabetic rats was expected to be more pronounced due…”
BackgroundFormulation and characterization of an oily-based system for oral delivery of insulin
Elsayed, A., Al-Remawi, M. M., Qinna, N. A., Farouk, A., & Badwan, A. A. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.06.004 · Cited by 95 · cited 1×
“Previously, the stage or severity of diabetes induction in animals was mainly judged by achieving a state of hyperglycemia that was described as an increase in the calculated baseline of glucose level post STZ treatment.(14,15) However, the extent at which the glucose level should be accepted in such studies was not a…”
BackgroundSelf-citationPalm, F., Ortsäter, H., Hansell, P., et al. (2004) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.472 · Cited by 85
Animal Models of Diabetes Mellitus for Islet Transplantation
Sakata, N., Yoshimatsu, G., Tsuchiya, H., Egawa, S., & Unno, M. (2012) · Experimental Diabetes Research · doi:10.1155/2012/256707 · Cited by 83 · cited 1×
“Many reports indicated that STZ is capable of producing mild to severe types of diabetes that vary according to the selected dose, strain, and age of animals, nutritional status, and route of administration, along with other factors.(9,10,12,13) Therefore, researchers are obliged to custom-design their”
BackgroundEffect of Acute Hyperglycemia on Insulin Secretion in Humans
Toschi, E., Camastra, S., Sironi, A. M., Masoni, A., Gastaldelli, A., Mari, A., Ferrannini, E., & Natali, A. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s130 · Cited by 82 · cited 1×
“During hyperglycemia, the body attempts to compensate normal glucose homeostasis by producing higher amounts of insulin.(23) Conversely, it has been reported that hyperglycemia can also induce pancreatic β-cell dysfunction, reduced β-cell mass, and insulin deficiency.”
BackgroundTyrberg, B., Andersson, A., & Borg, L. (2001) · General and Comparative Endocrinology · doi:10.1006/gcen.2001.7638 · Cited by 62
Pulsatile Insulin Secretion by Human Pancreatic Islets
Song, S. H. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.213 · Cited by 57
Grant, C. W., Duclos, S., Moran-Paul, C., Yahalom, B., Tirabassi, R. S., Arreaza-Rubín, G., Spain, L. M., & Guberski, D. L. (2012) · Europe PMC (PubMed Central) · Cited by 48
The diabetic β‐cell: hyperstimulated vs. hyperexcited
Nichols, C. G., & Remedi, M. S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01655.x · Cited by 36
Cañas, X., Fernández–Löpez, J., Ardèvol, A., Adán, C., Esteve, M., Rafecas, I., Remesar, X., & Alemany, M. (1995) · Endocrinology · doi:10.1210/endo.136.9.7649094 · Cited by 29
Oral Delivery of Insulin: Novel Approaches
Amani, M. (2012) · InTech eBooks · doi:10.5772/52265 · Cited by 23 · cited 1×
“Indeed, a previous work demonstrated that administrating 5 IU/kg of oral insulin nanoparticles to STZ diabetic rats reduced blood glucose to the same extent as the 50-IU/kg dose.(30) This result indicates that there is reservoir of insulin which keeps circulating the blood in its inactive form but ready to be activate…”
BackgroundReduced glucose clearance as the major determinant of postabsorptive hyperglycemia in diabetic rats
Wi, J. K., Kim, J. K., & Youn, J. H. (1998) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1998.274.2.e257 · Cited by 12
Thibault, C., Laury, M. C., Bailbé, D., Ktorza, A., & Portha, B. (1992) · Endocrinology · doi:10.1210/endo.130.5.1572279 · Cited by 12
Metadata
- Authors
- Qinna, N., & Badwan, A.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-05
- Volume
- 9
- Pages
- 2515
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1728276264
- Cited by
- 187
- References
- 28
- FWCI
- 9.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.